The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...
GLP-1 drugs manufactured by Eli Lily and Novo Nordisk will cost as much as $350 per month for eligible patients.
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
The U.S. Food and Drug Administration has approved Exelixis Inc.’s (NASDAQ:EXEL) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, ...
The most common drug class associated with registered nurse (RN) medication errors (ME) was cardiovascular drugs. These errors accounted for 24.7% of such preventable ...
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback